Trastuzumab emtansine: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

29 April 2024

  • curprev 15:2515:25, 29 April 2024‎ Alara E. Dagsali talk contribs‎ 40,575 bytes −35‎ No edit summary
  • curprev 15:2315:23, 29 April 2024‎ Alara E. Dagsali talk contribs‎ 40,610 bytes +40,610‎ Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment..."
Retrieved from "https://www.wikidoc.org/index.php/Trastuzumab_emtansine"